Plain-English translation of NCT05508347 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Nimotuzumab (Taixinsheng®) — a targeted antibody therapy designed to block cancer cell growth — combined with standard chemotherapy and radiation treatment for advanced throat cancer (nasopharyngeal carcinoma). The medication works by stopping tumor cells from receiving growth signals. Half of participants will receive the active medication alongside their chemotherapy and radiation, while the other half will receive a placebo (inactive treatment) to see if the medication truly helps.
Studies show that most nasopharyngeal carcinomas have high levels of a protein that helps cancer cells grow and spread. This trial exists to test whether blocking that protein with this targeted therapy can improve survival and shrink tumors better than chemotherapy and radiation alone.
You likely qualify if…
You likely don't qualify if…
You will receive 3 cycles of chemotherapy (docetaxel and cisplatin) combined with either the active medication or placebo (9 infusions). Following this, you will undergo 2–3 cycles of concurrent chemotherapy and radiation therapy, again combined with either the medication or placebo (7 more infusions). Throughout the trial, you will have regular blood tests, scans, and check-ins to monitor how well the treatment is working and manage any side effects. The entire treatment course typically spans several months.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China